iCAD to Present at the LD Micro 500 Virtual Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iCAD (NASDAQ: ICAD), a leader in medical technology for cancer detection, announced its participation in the LD 500 Virtual Conference from September 1 to 4, 2020. Michael Klein, the CEO, will present on September 1 at 11:00 AM ET and engage in one-on-one meetings. The presentation will be available via a live audio webcast. For more details about the conference and scheduling individual meetings, participants can contact LD Micro representatives.
Details
News Market Reaction – ICAD
The recorded move for ICAD in the trading session of this news was -0.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHUA, N.H., Aug. 27, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that management will present at the LD 500 Virtual Conference, hosted by LD Micro and taking place virtually September 1 – 4, 2020.
Michael Klein, Chief Executive of iCAD, is scheduled to host a virtual presentation during the conference as follows and will participate in one-on-one meetings throughout the day.
| LD 500 Virtual Investor Conference | |
| Date: | Tuesday, September 1, 2020 |
| Time: | 11:00am Eastern Time – Track 4 |
| Webcast: | https://www.webcaster4.com/Webcast/Page/2019/36075 |
A live audio webcast and archive of the conference presentation will be available using the webcast link above. For more information on the LD 500 virtual investor conference or to schedule a one-on-one, please contact your LD Micro representative.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
Contact:
Media Inquiries:
Jessica Burns, iCAD
+1-201-423-4492
jburns@icadmed.com
Investor Relations:
Jeremy Feffer, LifeSci Advisors
+ 1-212-915-2568
jeremy@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.